Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Feb 17, 2011

Premium

NanoString Technologies this week announced that it has hired Chris Grimley as vice president of marketing, and Katherine Webster as vice president of worldwide sales.

Grimley joins NanoString from Agilent Technologies, where he was most recently senior director of genomics marketing, leading strategic and product marketing programs across microarrays, target enrichment products for next-generation sequencing, qPCR systems, bioreagents, and software solutions. His prior experience includes 14 years at Applied Biosystems (now Life Technologies) where he held a number of senior product management positions, including directing the real-time PCR and microarray system product lines. He began his career as a research associate at Genentech. Grimley holds a BS in biochemistry from San Francisco State University.

Webster joins NanoString from Qiagen where she was senior sales director for the life science business. Prior executive management positions include vice president of sales for the 454 Sequencing Center at 454 Life Sciences (now part of Roche); and president of Biotage Biosystems Division Worldwide. Her past experience also includes senior management positions at Molecular Staging, Celera Genomics, Chemdex, and Applied Biosystems (now Life Technologies). Webster holds a BS in Chemistry from the State University of New York at Syracuse.

Both executives will play a key role in preparing the company for worldwide sales and marketing of high-value clinical diagnostics products based on the nCounter System, pending appropriate regulatory approvals, NanoString said.

The Scan

Follow-Up Data Requests to Biobank Participants Ineffective, Study Finds

An effort to recontact biobank enrollees for additional information reports low participation in a new BMJ Open study.

Study Finds Widespread Transmission of Resistant Bacteria in Vietnam Hospitals

A sequencing study in The Lancet Microbe finds widespread transmission of drug-resistant Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii in two Vietnam ICUs.

Novel Brain Cell Organoids Show Promise for Autism Research

University of Utah researchers report in Nature Communications on their development of brain cell organoids to study SHANK3-related autism.

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.